Clinical trial data and effectiveness analysis of ruxolitinib cream (Opzelura) in the treatment of vitiligo

Ruxolitinib cream (Opzelura, generic name: ruxolitinib) is the first US FDA approved for the treatment of non-segmental vitiligo (nonsegmental vitiligo, NSV) topical Januskinase (JAK) inhibitor. It has shown remarkable efficacy in clinical trials, especially in the repigmentation of skin lesions on the face and body, and has become a new hope for patients with vitiligo.

1.Clinical trial data

Opzelura’s efficacy mainly comes from two key 3 phase clinical trials: TRuE-V1( span>NCT04052425) and TRuE-V2 (NCT04057573). These studies evaluated the efficacy of ruxolitinibcream at a concentration of 1.5% twice daily (BID ) in the treatment of patients with non-segmental vitiligo. At 24 weeks, approximately 36%of patients had facial Vitiligo Area Scoring Index(F-VASI) achieved at least 75% improvement (F-VASI75 ), and in terms of the T-VASI score of systemic skin lesions, about 30% of patients reached F-VASI75.

Further long-term data (up to 104 weeks) show that the treatment effect is sustained and stable, with some patients achieving F-VASIscores of 90% or above (F-VASI90) in F-VASIscores. These results demonstrate that Opzelura is not only effective in the short term but also maintains efficacy over long-term treatment.

2.Safety and Tolerability

The safety of Opzelura has been fully evaluated in clinical trials. The most common adverse reactions include application site acne, pruritus, upper respiratory tract infection, headache, urinary tract infection, pyrexia, and localized erythema. These adverse reactions are usually mild to moderate and well tolerated by most patients. In long-term use, no serious systemic adverse events such as thrombocytopenia, anemia, or granulocytopenia were observed.

3.Indications and users

Opzelurais suitable for local treatment of non-segmental vitiligo in non-immune-compromised adult and adolescent patients 12 years old and above. It provides new treatment options for patients for whom traditional treatments are ineffective or unsuitable. However, it is unclear whether Opzelura is safe and effective in children under 12 years of age with vitiligo, so use in this population should be cautious.

Opzelura (ruxolitinib cream) is the first topical JAK inhibitor approved by the FDA for the treatment of non-segmental vitiligo, which has demonstrated significant efficacy and good safety in clinical trials. It provides a new treatment option for patients with vitiligo, especially those with facial and systemic lesions. However, patients should be under the guidance of a doctor when using Opzelura to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/